Biogen, Eisai to shift some Alzheimer's drug production to US / Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short / Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction / Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction / Biogen is buying up an immune drug developer for $1.8 billion

Biogen

Updated: 129d ago

ShareCopied to clipboard

Biogen is a company. It is a private company in Cambridge, the United States. It's current CEO is Christopher A. Viehbacher and is part of the Health Care sector, specifically in the Pharmaceuticals industry.

Key facts

city: Cambridge
country: United States
employees: 7,605 people
revenues: 9.7B $
company type: private
sector: Health Care
industry: Pharmaceuticals
CEO: Christopher A. Viehbacher
ESG score: 72.77 / 100

See more facts

Extract data

Download datasets about Biogen:

Dataset of stocks from Biogen

Biogen is one of the companies in the United States, companies in Pharmaceuticals, companies in Health Care, companies in Cambridge and 3,456,808 companies in our database.

Talking Points

Home | Biogen
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.